AI Article Synopsis
- PD-1 is a key protein that helps to suppress the immune response against tumors, making it a critical target for cancer treatments called immune checkpoint inhibitors (ICIs).
- Researchers developed a new strategy to create effective chimeric anti-PD-1 molecules, which combine features from different sources to improve cancer therapy.
- The new chimeric antibodies created demonstrated strong ability to bind to PD-1, activating T cells similarly to existing treatments, marking them as promising candidates for future immunotherapy development.
Article Abstract
Programmed cell death protein 1 (PD-1) plays a significant role in suppressing antitumor immune responses. Cancer treatment with immune checkpoint inhibitors (ICIs) targeting PD-1 has been approved to treat numerous cancers and is the backbone of cancer immunotherapy. Anti-PD-1 molecule is necessary for next-generation cancer immunotherapy to further improve clinical efficacy and safety as well as integrate into novel treatment combinations or platforms. We developed a highly efficient hybridoma generation and screening strategy to generate high-potency chimeric anti-PD-1 molecules. Using this strategy, we successfully generated several mouse hybridoma and mouse/human chimeric clones that produced high-affinity antibodies against human PD-1 with high-quality in vitro PD-1/PD-L1 binding blockade and T cell activation activities. The lead chimeric prototypes exhibited overall in vitro performance comparable to commercially available anti-PD-1 antibodies and could be qualified as promising therapeutic candidates for further development toward immuno-oncology applications.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588028 | PMC |
| http://dx.doi.org/10.1038/s41598-022-20560-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High-yield production of lignin nanoparticle photonic glasses.
Green Chem
January 2025
Department of Materials and Environmental Chemistry, Stockholm University SE-106 91 Stockholm Sweden
Lignin has emerged as a sustainable alternative to fossil-based polymers in advanced materials such as photonics. However, current methods for preparing photonic lignin materials are limited by non-benign organic solvents and low production yields. In this work, we present a highly efficient process that enables the production of photonic glasses with yields ranging from 48% to 72%, depending on the size of the lignin nanoparticles obtained from herbaceous soda lignin, softwood kraft lignin, and hardwood organosolv lignin.
View Article and Find Full Text PDFA chemically modified DNAzyme-based electrochemical sensor for binary and highly sensitive detection of reactive oxygen species.
Chem Sci
January 2025
School of Chemistry and Materials Science, Jiangsu Normal University Xuzhou 221116 China
Reactive oxygen species (ROS) play a critical role in regulating various physiological processes. To gain a comprehensive understanding of their distinct functions in different physiological events, it is imperative to detect binary ROS simultaneously. However, the development of the sensing method capable of binary ROS detection remains a significant challenge.
View Article and Find Full Text PDFObjective: This study aims to evaluate the clinical efficacy of electro-pneumatic intracorporeal lithotripsy for the treatment of salivary gland stones.
Study Design: A prospective cohort study of patients diagnosed with obstructive salivary gland syndrome, where basket-assisted sialendoscopy alone failed to remove the calculi.
Setting: This study was conducted at the "Queen Maria" Military Hospital in Brașov, Romania, and a private practice, between February 2023 and May 2024.
Exploring using HBsAg to predict interferon treatment course to achieve clinical cure in chronic hepatitis B patients: a clinical study.
Front Immunol
January 2025
Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, Tianjin, China.
Objective: Although pegylated interferon α-2b (PEG-IFN α-2b) therapy for chronic hepatitis B has received increasing attention, determining the optimal treatment course remains challenging. This research aimed to develop an efficient model for predicting interferon (IFN) treatment course.
Methods: Patients with chronic hepatitis B, undergoing PEG-IFN α-2b monotherapy or combined with NAs (Nucleoside Analogs), were recruited from January 2018 to December 2023 at Tianjin Third Central Hospital.
Disentangling protein metabolic costs in human cells and tissues.
PNAS Nexus
January 2025
Logic of Genomic Systems Laboratory (CNB-CSIC), Madrid E-28049, Spain.
While more data are becoming available on gene activity at different levels of biological organization, our understanding of the underlying biology remains incomplete. Here, we introduce a metabolic efficiency framework that considers highly expressed proteins (HEPs), their length, and biosynthetic costs in terms of the amino acids (AAs) they contain to address the observed balance of expression costs in cells, tissues, and cancer transformation. Notably, the combined set of HEPs in either cells or tissues shows an abundance of large and costly proteins, yet tissues compensate this with short HEPs comprised of economical AAs, indicating a stronger tendency toward mitigating costs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!